Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents

Breast Cancer Research

Volumn 11, Issue 2, 2009, Pages

  Untch, Michael ^a   von Minckwitz, Gunter ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GBG Forschungs GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; METHOTREXATE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LOADING DRUG DOSE; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAIL COLOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 68349118222     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2227     Document Type: Review

References (17)

1. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1930. 10.1093/annonc/mdm201, 17998286.
2. von Minckwitz G. Can we tailor chemotherapy based on preliminary response? General session X: multidisciplinary implications of preoperative therapy. Paper presented at: American Society of Clinical Oncology 2008 Breast Cancer Symposium; 5-7 September 2008; Washington, DC
3. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998, 16:93-100.
4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, (30):96-102.
6. Hage JA, Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19:4224-4237.
7. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, . National Surgical Adjuvant Breast and Bowel Project Protocol B-27 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174. 10.1200/JCO.2003.12.005, 14559892, National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
8. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative dox-orubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027. 10.1200/JCO.2005.04.1665, 16606972.
9. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P, Bonadonna G, for the ECTO Study G. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 2002, 21:34a. Abstract 132..
10. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clinical Oncol 2009,
11. Von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as pre-operative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005, 23:2676-2678. 10.1200/JCO.2005.05.078, 15837982.
12. Von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, . German Breast Group Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100:542-551. 10.1093/jnci/djn085, 18398097, German Breast Group.
13. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, . German Breast Group Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008, 100:552-562. 10.1093/jnci/djn089, 18398094, German Breast Group.
14. Untch M. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study "GeparQuattro". Paper presented at: 6th European Breast Cancer Conference; 15-19 April 2008; Berlin, Germany Abstract 0450..
15. Untch M, Stoeckl D, Konecny G, Kreienberg R, Thommsen C, Camara O, Moebus V, Kuehn T, DuBois A, Lueck HJ, Gitsch G, Fasching P. A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. Paper presented at: 28th Annual San Antonio Breast Cancer Symposium; 8-11 December 2005; San Antonio, TX Abstract 1064..
16. Untch M, Fasching PA, Stöckl D, Kahlert S, Conrad U, Camara O, Fett W, Kurzeder C, Lück HJ, Loibl S, von Minckwitz G. PREPARE trial. A randomized phase III trial comparing preoperative, dose dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery. ASCO 2008. J Clin Oncol 2008, 26(suppl):abstract 517.
17. von Minckwitz G, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. Paper presented at: 30th Annual San Antonio Breast Cancer Symposium; 13-16 December 2007; San Antonio, TX Abstract 79..